ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
US Tech 100
19,884.80
0.46%
Dow Jones
40,211.72
0.53%
Brent Oil
84.005
-0.40%
Bitcoin
64,014.20
-1.29%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Lyra Therapeutics Inc (LYRA) Quote

Lyra Therapeutics Inc

Lyra Therapeutics Inc (LYRA)

NASDAQ
0.305
0.014
(4.81%)
Closed July 16 4:00PM
Delayed by 15 minutes
0.30
-0.005
(-1.64%)
After Hours: 7:54PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.30
Bid
0.30
Ask
0.3001
Volume
1,252,682
0.2892 Day's Range 0.305
0.2532 52 Week Range 6.79
Market Cap
17.741M
Previous Close
0.291
Open
0.2892
Last Trade
13
@
0.3
Last Trade Time
Financial Volume
$ 374,039
VWAP
0.29859
Average Volume (3m)
4,151,825
Shares Outstanding
60,964,859
Dividend Yield
-
PE Ratio
-0.29
Earnings Per Share (EPS)
-1.03
Revenue
1.56M
Net Profit
-62.68M

About Lyra Therapeutics Inc

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precis... Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
lyratherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Lyra Therapeutics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker LYRA. The last closing price for Lyra Therapeutics was $0.29. Over the last year, Lyra Therapeutics shares have traded in a share price range of $ 0.2532 to $ 6.79.

Lyra Therapeutics currently has 60,964,859 shares outstanding. The market capitalization of Lyra Therapeutics is $17.74 million. Lyra Therapeutics has a price to earnings ratio (PE ratio) of -0.29.

LYRA Latest News

More News

Form 8-K - Current report

June 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 14 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 14 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 14 2024
Edgar (US Regulatory)

Form 8-K/A - Current report: [Amend]

June 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 21 2024
Edgar (US Regulatory)

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by...

May 21 2024
GlobeNewswire Inc.

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq:...

May 06 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.028110.33468186830.27190.3050.261113340290.28254101CS
40.013.448275862070.290.30750.253217496730.27168515CS
12-4.9-94.23076923085.25.650.253241518250.51455842CS
26-5.05-94.39252336455.356.790.253220773860.96984001CS
52-2.76-90.19607843143.066.790.253211784731.36417418CS
156-7.33-96.06815203157.639.980.25324434791.80727726CS
260-20.7-98.571428571421220.25323494662.79111561CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
SHOTWSafety Shot Inc
$ 0.41
(115.79%)
7.56k
DATSDatChat Inc
$ 1.89
(81.73%)
54.75M
CYNCYNGN Inc
$ 9.18
(53.77%)
17.79M
SCNIScinai Immunotherapeutics Ltd
$ 5.80
(42.86%)
29.37M
ASLNASLAN Pharmaceuticals Ltd
$ 1.36
(-46.67%)
1.16M
KZIAKazia Therapeutics Ltd
$ 0.5593
(-37.56%)
15.34M
LCFYLocafy Ltd
$ 3.5597
(-36.32%)
584.38k
NAASNaaS Technology Inc
$ 2.82
(-33.02%)
1.94M
ZENVZenvia Inc
$ 1.67
(-26.75%)
658.26k
FFIEFaraday Future Intelligent Electric Inc
$ 0.5152
(22.09%)
217.92M
NVDANVIDIA Corporation
$ 128.44
(-0.62%)
208.32M
SQQQProShares UltraPro Short QQQ
$ 7.46
(-0.67%)
155.14M
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
TSLATesla Inc
$ 252.64
(1.78%)
147.31M

LYRA Discussion

View Posts
BigBadWolf BigBadWolf 4 weeks ago
DDAmanda finds them early so that Han's (he provided the name pumping testimonials) can sell off his early buys while he's pumping to his paid subscribers. Want proof DDAmanda $subscribers PM me for verification or simply check my posting history for the mud this P_G waddles in..
https://lyratherapeutics.com/
👍️0
Zardiw Zardiw 4 weeks ago
Well, 6 weeks ago she was $5: $LYRA Chart from #DDAmanda - #1 Stock Screener :

Find Winners Early:



Z
👍️0
Termite7 Termite7 4 weeks ago
Who? .....How high for LYRA? .......Thanks!!!
👍️0
Zardiw Zardiw 1 month ago
Nice list.........$LYRA is due.......according to #DDAmanda.

Z
👍️0
Termite7 Termite7 1 month ago
Oversold!!! ......https://finviz.com/screener.ashx?v=110&s=ta_oversold&o=change
👍️0
Zardiw Zardiw 2 months ago
$LYRA Book Value is $1.27 ......trading at .34 ........or 1/4 the BV........

Z
👍️ 1
INV4 INV4 2 months ago
LYRA Institutional Holdings
Ownership Summary

Institutional Ownership • 74.73%
Total Shares Outstanding (millions) • 61
Total Value of Holdings (millions) • $16

Active Positions • Holders • Shares
Increased Positions • 54 • 9,224,767
Decreased Positions • 19 • 6,026,566
Held Positions • 11 • 30,304,888

Institutional Holders: 84
Total Shares Held: 45,556,221

$BLEG

LYRA Analyst Research
Lyra Therapeutics, Inc. Common Stock (LYRA) Analyst Research
LYRA Earnings Consensus

CONSENSUS
Buy
Based on 6 analysts offering recommendations for 'LYRA'.

Analyst Price Targets
CONSENSUS
$0.95

Based on analysts offering 12 month price targets for LYRA in the last 3 months.
The average price target is $0.95 with a high estimate of $2 and a low estimate of $0.35.

https://www.nasdaq.com/market-activity/stocks/lyra/analyst-research

$LYRA
👍️0
Zardiw Zardiw 2 months ago
$LYRA Bounce anytime now...............

Z
👍️ 1
INV4 INV4 2 months ago
Let's see when it bounces 😀

$LYRA
👍️0
glenn1919 glenn1919 2 months ago
LYRA.........................................https://stockcharts.com/h-sc/ui?s=LYRA&p=W&b=5&g=0&id=p86431144783
👍️0
Zardiw Zardiw 2 months ago
Yes. Expecting a nice $LYRA Bounce..............

Z
👍️0
Dennis14 Dennis14 2 months ago
Relative Strength Index is at 12 this is way over sold.
👍️0
Zardiw Zardiw 2 months ago
$LYRA Book Value: $1.28 ....currently at .43 ...

Z
👍️0
Dennis14 Dennis14 2 months ago
Bought in this morning at .42, I believe this will be back to at least 1 or 2 bucks.
👍️0
axelvento axelvento 2 months ago
game over: announced topline results from the Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint
👍️0
Monksdream Monksdream 3 months ago
LYRA under $10

👍️0
Monksdream Monksdream 4 months ago
LYRA under $10
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA...NOT HOLDING INTO ER
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA...LETS SEE 7.00
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA...EXPLODING!!!!!
👍️0
Monksdream Monksdream 4 months ago
LYRA 10Q due March 14
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA...BEAUTIFUL BREAK OUT
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA....BIO BEAST!
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA...HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA...MOVES ON AIR!!!
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA...HERE WE GO
👍️0
Monksdream Monksdream 4 months ago
LYRA 10Q due March 7
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA..WHAT A BEAUTY...NOBODY TALKING!!!
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LYRA...NEXT BIO BEAST READY TO BEAST
👍️0
Monksdream Monksdream 10 months ago
LYRA No 3 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

NASDAQ
LYRA
Lyra Therapeutics
NYSE
KBDC
Kayne Anderson Bdc
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved